Effects of the synthetic peptide derived from the reactive site of EcTI on inflammation, renovation and oxidative stress in a model of Asthma-COPD Overlay Syndrome (ACOS)

• Grant number: 19/27807-8
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): August 01, 2020
• Effective date (End): July 31, 2022
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Iolanda de Fátima Lopes Calvo Tibério
• Grantee: Henrique Tibucheski dos Santos
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated research grant: 18/02537-5 - Characterization of asthma-COPD overlap syndrome (ACOS): experimental and clinical studies, AP.TEM

Abstract

Experimental therapy laboratory I (LIM-20) is a multidisciplinary group of researchers who have been working for several years on the mechanisms of asthma and chronic obstructive pulmonary disease (COPD) development, with a focus in the mechanisms of modulation and pathophysiology of these combining experimental and clinical studies in patients with asthma and COPD. Both in clinical practice and in scientific research, obstructive respiratory diseases - asthma and COPD - are widely studied, with defined criteria and pathophysiological mechanisms. However, in recent years, a variant of these diseases has been described, and overlapping features common to both, with clinical manifestations similar to those observed in COPD, but with a significant response to the use of bronchodilators. This clinical entity was called asthma-COPD overlap syndrome (ACOS). Despite this classification, there is no consensus in the literature about the inflammatory profile, oxidative stress and pulmonary tissue remodeling in these patients, showing a lack of understanding of the pathophysiology of the disease and the mechanisms that could modulate these responses. ACOS is an airway disease characterized by a fixed airflow obstruction with features common to both asthma and COPD, but a more specific definition could not yet be established given the lack of scientific evidence on the subject. One of the most relevant implications in the diagnosis and understanding of the pathophysiology of ACOS is the therapeutics and modulation mechanisms to be adopted for these patients and based on all these similarities and differences in the definition and pathophysiology of ACOS, it is understandable that further investigations are necessary related to this disease. Thus, the central objective of this project is the development of a set of experimental studies that aims to deepen the mechanisms of modulation and pathophysiology of ACOS. In this way, we will carry out seven experimental studies to evaluate the mechanisms of the effects of anti-IL17 action, peptide and protease inhibitors, cytokine signaling suppressor proteins (SOCS) and transcription activators (STAT), as well as occupational influences (chlorine and pollution) and interval training in the experimental model of asthma-COPD overlap syndrome (ACOS).

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

CAMARGO, L.; BARBOSA, J.; SILVA, L.; JOAO, J.; SANTOS, H.; SARAIVA-ROMANHOLO, B.; FUKUZAKI, S.; BEZERRA, S.; PRADO, C.; LOPES, F.; et al. Does Treatment with a Plant Proteinase Inhibitor, Enterolobium Contortisiliquum Contribute to the Control of Inflammation, Remodeling and Oxidative Stress in Mice with Asthma-COPD Overlap (ACO)?. American Journal of Respiratory and Critical Care Medicine, v. 205, p. 2-pg., 2022-05-01. (18/02537-5, 19/27807-8)